Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

ClinicalTrials.gov ID: NCT07650916

Public ClinicalTrials.gov record NCT07650916. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Aug 3, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Cabotegravir Ultra Long-acting Plus Rilpivirine Ultra Long-acting or Cabotegravir Long-acting Plus Rilpivirine Long-acting in Adults and Adolescents With HIV Who Are Virologically Suppressed on ART

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

Study identification

NCT ID
NCT07650916
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
ViiV Healthcare
Industry
Enrollment
564 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 24, 2026
Primary completion
Sep 3, 2029
Completion
Sep 3, 2029
Last update posted
Aug 2, 2026

2026 – 2029

United States locations

U.S. sites
35
U.S. states
19
U.S. cities
32
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85015 Recruiting
GSK Investigational Site Bakersfield California 93301 Recruiting
GSK Investigational Site Los Angeles California 90027 Recruiting
GSK Investigational Site Los Angeles California 90036 Recruiting
GSK Investigational Site San Diego California 92103 Recruiting
GSK Investigational Site New Haven Connecticut 06510 Recruiting
GSK Investigational Site Washington D.C. District of Columbia 20017 Recruiting
GSK Investigational Site DeLand Florida 32720 Recruiting
GSK Investigational Site Fort Lauderdale Florida 33316 Recruiting
GSK Investigational Site Ft. Pierce Florida 34982 Recruiting
GSK Investigational Site Miami Florida 33136 Recruiting
GSK Investigational Site Orlando Florida 32803 Recruiting
GSK Investigational Site Pensacola Florida 32503 Recruiting
GSK Investigational Site Vero Beach Florida 32960 Recruiting
GSK Investigational Site West Palm Beach Florida 33407 Recruiting
GSK Investigational Site West Palm Beach Florida 33409 Recruiting
GSK Investigational Site Decatur Georgia 30033 Recruiting
GSK Investigational Site Grosse Pointe Woods Michigan 48236 Recruiting
GSK Investigational Site Kansas City Missouri 64111 Recruiting
GSK Investigational Site Las Vegas Nevada 89101 Recruiting
GSK Investigational Site Newark New Jersey 07102 Recruiting
GSK Investigational Site Santa Fe New Mexico 87505 Recruiting
GSK Investigational Site Stony Brook New York 11794 Recruiting
GSK Investigational Site Syracuse New York 13057 Recruiting
GSK Investigational Site Greensboro North Carolina 27401 Recruiting
GSK Investigational Site Columbus Ohio 43210 Recruiting
GSK Investigational Site Philadelphia Pennsylvania 19104 Recruiting
GSK Investigational Site Austin Texas 78705 Recruiting
GSK Investigational Site Dallas Texas 75219 Recruiting
GSK Investigational Site Dallas Texas 75246 Recruiting
GSK Investigational Site El Paso Texas 79902 Recruiting
GSK Investigational Site Houston Texas 77098 Recruiting
GSK Investigational Site Salt Lake City Utah 84102 Recruiting
GSK Investigational Site Lynchburg Virginia 24501 Recruiting
GSK Investigational Site Seattle Washington 98104 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

Recently updated HIV Infections trials

Other public records listing HIV Infections. Sorted by last update posted; newest first. Not a recommendation.

All HIV Infections trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07650916, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 2, 2026 · Synced Aug 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07650916 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →